ONC-2014-001: An open-label phase II study of regorafenib in patients with metastatic solid tumors who have progressed after standard therapy - RESOUND

被引：3
|
作者：
Bozzarelli, S. [1 ]
Rimassa, L. [1 ]
Giordano, L. [1 ]
Garassino, I. [1 ]
Marrari, A. [1 ]
Tronconi, M. C. [1 ]
De Sanctis, R. M. [1 ]
Cavina, R. [1 ]
Baretti, M. [1 ]
Personeni, N. [1 ]
Pressiani, T. [1 ]
Santoro, A. [1 ]
机构：
[1] Humanitas Clin & Res Ctr, Humanitas Canc Ctr, Rozzano, MI, Italy
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
10.1093/annonc/mdv348.59
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
R59
引用
收藏
页码：149 / 149
页数：1
相关论文
共 50 条
  • [21] A phase II study of patupilone in patients with metastatic hormone refractory prostate cancer (HRPC) who have progressed after docetaxel
    Chi, K. N.
    Beardsley, E. K.
    Venner, P. M.
    Eigl, B. J.
    Hotte, S. J.
    Ko, Y.
    Saad, F.
    Winquist, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [22] An open-label, multicenter, phase I study of ATG-022 in patients with advanced/metastatic solid tumors (CLINCH).
    Bishnoi, Sarwan
    Cao, Dan
    Mendis, Shehara Ramyalini
    Coward, Jim
    Zhao, Jun
    Xie, Hui
    Zheng, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [23] PD-1 Inhibitor Combined With Radiotherapy and GM-CSF (PRaG) in Patients With Metastatic Solid Tumors: An Open-Label Phase II Study
    Kong, Yuehong
    Zhao, Xiangrong
    Xu, Meiling
    Pan, Jie
    Ma, Yifu
    Zou, Li
    Peng, Qiliang
    Zhang, Junjun
    Su, Cunjin
    Xu, Zhi
    Zhou, Wei
    Peng, Yong
    Yang, Jiabao
    Zhou, Chengliang
    Li, Yujia
    Guo, Qiuchen
    Chen, Guangqiang
    Wu, Hongya
    Xing, Pengfei
    Zhang, Liyuan
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [24] Safety and efficacy of cobimetinib plus atezolizumab in patients with solid tumors: a phase II, open-label, multicenter, multicohort study
    Sherman, E.
    Lee, J. L.
    Debruyne, P. R.
    Keam, B.
    Shin, S. J.
    Gramza, A.
    Caro, I.
    Amin, R.
    Shah, K.
    Yan, Y.
    Huddart, R.
    Powles, T.
    ESMO OPEN, 2023, 8 (02)
  • [25] Multicenter, open-label phase II study of daily oral regorafenib for chemotherapy-refractory, metastatic and locally advanced angiosarcoma
    Agulnik, M.
    van Tine, B. A.
    Attia, S.
    Rademaker, A.
    Milhem, M.
    Okuno, S. H.
    ANNALS OF ONCOLOGY, 2018, 29 : 592 - 592
  • [26] Phase I, open-label study of olaparib plus cisplatin in patients with advanced solid tumors
    Balmana, Judith
    Tung, Nadine M.
    Isakoff, Steven J.
    Grana, Begona
    Ryan, Paula D.
    Rafi, Rezvan
    Tracy, Michael
    Winer, Eric
    Baselga, Jose
    Garber, Judy Ellen
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [27] An open-label phase I study to evaluate the safety, tolerability and preliminary efficacy of YY001 in patients with advanced solid tumors
    Xue, Liqiong
    Tang, Wenbo
    Zhou, Huan
    Liu, Mulin
    Liu, Yuanyuan
    Wang, Jinhua
    Chen, Jianfeng
    Liu, Mingyao
    Guo, Ye
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [28] OPEN-LABEL PHASE II STUDY OF SORAFENIB plus DACARBAZINE IN PATIENTS WITH ADVANCED METASTATIC MELANOMA
    Gonzalez-Larriba, J. L.
    Guillem, V.
    Marmol, M.
    Valladares, M.
    Arrivi, A.
    Pastor, P.
    Garcia-Garcia, M.
    ANNALS OF ONCOLOGY, 2008, 19 : 246 - 246
  • [29] A single-arm, open-label, multicenter phase II trial (CheckMate 172) of nivolumab (NIVO) safety in European patients (pts) with advanced melanoma (MEL) who have progressed after ipilimumab therapy (IPI).
    Schadendorf, Dirk
    Ascierto, Paolo Antonio
    Espinosa, Enrique
    Haanen, John B. A. G.
    Hermann, Frank
    Nathan, Paul D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [30] CaboPoint, a phase II, open-label study of cabozantinib as second-line therapy for patients with clear cell metastatic renal cell carcinoma (RCC), whose disease progressed after therapy with checkpoint inhibitors (CPIs)
    Albiges, Laurence
    Schmidinger, Manuela
    Pioger, Naila Taguieva
    Perol, David
    Gruenwald, Viktor
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
12345